Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma
Namrata Singh(University of Washington), Brian K. Link(University of Iowa), Thomas M. Habermann(Mayo Clinic in Arizona), Zuhair K. Ballas(University of Iowa), Sarah L. Mott(University of Iowa), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Susan L. Slager(Mayo Clinic), James R. Cerhan(Mayo Clinic), Andrew L. Feldman(Mayo Clinic in Arizona), Umar Farooq(Wake Forest University), Sergei Syrbu(University of Iowa), Ashley McCarthy(University of Iowa Hospitals and Clinics), Thomas E. Witzig(WinnMed)
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Body-Mass Index and Mortality among 1.46 Million White Adults
|New England Journal of Medicine|2010|2.3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k